Clinical trial · no report yet · Phase 2
NCT06767800
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
- NCT06767800 ↗
- Recruiting
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Chemotherapy With Behmosubstituted Monoclonalb/Pembrolizumab ± Chemotherapy in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy; TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- Arms
- TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy · Experimental
- TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy · Experimental
- TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy · Experimental
- Enrollment
- 204 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Start
- Nov 21, 2024
- Primary completion
- Sep 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06767800 · updated Jul 30, 2025